Rol van bisfosfonaten bij prostaatcarcinoom
Samenvatting
Bij 65-75% van de mannen met een gevorderd ziektestadium metastaseert de prostaatkanker naar het bot. Bovendien hebben patiënten met prostaatkanker vaak verschillende andere risicofactoren voor botcomplicaties, zoals osteoporose en androgeendeprivatietherapie. Maligne botlaesies kunnen de botstructuur aantasten. Dat kan onder andere resulteren in pathologische fracturen, compressie van het ruggenmerg en ernstige botpijnen. Deze skeletal-related events (SRE’s) hebben een negatieve impact op de kwaliteit van leven van de patiënt.
De effecten van de prostaatkanker zelf en de behandeling ervan resulteren in een verminderde integriteit van het bot en vormen daarmee een uitdaging bij de behandeling. Evidence vanuit (pre)klinische studies wijzen erop dat op het bot gerichte therapieën, zoals bisfosfonaten, nuttig kunnen zijn bij het behandelen en voorkómen van botmetastasen en de daaraan gerelateerde complicaties.
Trefwoorden:
prostaatkanker, botcomplicaties, behandeling, bisfosfonatenSummary
Bisphosphonates and prostate cancer
In 65-75% of men with advanced prostate cancer, the tumor metastasizes to the bone. In addition, patients with prostate cancer often have a variety of other risk factors for the development of bone-related complications, e.g. osteoporosis and androgen-deprivation therapy. Malign bone lesions could destroy the bone structure, which could results in pathological fractures, bone marrow compressions and severe bone pain. These skeletal-related events (SREs) have a negative impact on the quality of life of the patient.
The effects of the prostate tumor itself and the treatment result in a decreased integrity of the bone and are a therapeutic challenge. Evidence from (pre)clinical studies suggest that bone-directed therapies, like bisphosphonates, could be helpful in preventing prevention bone metastases and related complications.
Key words:
Prostate cancer, Bone complications, Treatment, BisphosphonatesLiteratuur
- 1.Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol. 2006 Mar;49(3):429-40.PubMedCrossRefGoogle Scholar
- 2.Saad F. Impact of bone metastases on patient’s quality of life and importance of treatment. Eur Urol. 2006; suppl.5:547-50.CrossRefGoogle Scholar
- 3.Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008 Mar;19(3):420-32.PubMedCrossRefGoogle Scholar
- 4.Fitzpatrick JM, Colombel M, Saad F, et al. Treatment strategies in advanced prostate cancer/genitourinary malignancies: the use of bisphosphonates across the continuum. Eur Urol. 2009;suppl8:733-7.Google Scholar
- 5.Israeli RS. Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy. Rev Urol. 2008 Spring;10(2):99-110.PubMedGoogle Scholar
- 6.Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol. 2006 Jan-Feb;24(1):4-12.PubMedCrossRefGoogle Scholar
- 7.Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011 Mar 5;377(9768):813-22.PubMedCrossRefGoogle Scholar
- 8.Dearnaley DP, Mason MD, Parmar MK, et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009 Sep;10(9):872-6.PubMedCrossRefGoogle Scholar
- 9.Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004 Jun 2;96(11):879-82.PubMedCrossRefGoogle Scholar
- 10.Somford MP, Thomassen BJ, Draijer WF. Femurfracturen door langdurig bisfosfonaatgebruik. Ned Tijdschr Geneeskd. 2010;154:A1218.Google Scholar
- 11.SPmC zoledroninezuur productinformatie en bijwerkingenprofiel.Google Scholar
- 12.IKNL. Landelijke richtlijn Prostaatcarcinoom; versie 1.0. Juli 2007.Google Scholar
- 13.Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castrationresistant prostate cancer. Eur Urol. 2011 Apr;59(4):572-83.PubMedCrossRefGoogle Scholar